Voluntary Announcement - First patient enrolled in Phase II clinical trial of bispecial antibody M701 malignant pleural effusion
Date of board meeting
Monthly Return of equity Issuer on Movements in Securities for the month ended 29 February 2024
Notification Letters and Reply Notes to Registered Shareholders - Arrangements for the electronic release of corporate communications
Notification Letters and Reply Notes to non-registered Shareholders - Arrangements for electronic distribution of corporate communications
Monthly return of equity Issuer on movements in securities for the month ended 31 January 2024
Monthly Return of equity Issuer on movements in securities for the month ended 31 December 2023
Monthly Return of equity Issuer on movements in Securities for the month ended 30 November 2023
章程
Poll results of the first Extraordinary General Meeting in 2023